AMPH
Amphastar Pharmaceuticals, Inc.
25.90$
+2.1%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 35.2% | 32.4% | 35.3% | 32.4% | 35.3% | 33.9% | 36.2% | 36.0% | 38.4% | 39.0% | 38.4% | 36.2% | |
| 17.3% | 9.5% | 12.8% | 12.7% | 12.4% | 9.6% | 11.2% | 11.6% | 13.0% | 10.4% | 10.4% | 12.8% | |
| 19.4% | 17.0% | 18.4% | 14.6% | 16.2% | 14.1% | 14.6% | 14.3% | 16.7% | 17.4% | 17.9% | 16.6% | |
| 7.7% | 7.6% | 8.8% | 8.9% | 9.4% | 8.8% | 8.9% | 8.3% | 8.8% | 8.8% | 9.0% | 8.3% | |
| 7.1% | 7.0% | 7.3% | 8.2% | 8.4% | 9.7% | 11.4% | 11.9% | 11.2% | 10.9% | 10.3% | 10.3% | |
| 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | |
| 39.9% | 40.3% | 38.4% | 40.1% | 38.3% | 37.3% | 35.7% | 35.6% | 34.1% | 34.5% | 33.8% | 32.3% | |
| 61.5% | 57.7% | 57.3% | 52.2% | 52.9% | 53.6% | 53.8% | 53.1% | 53.4% | 51.6% | 53.1% | 55.9% | |
| 16.7% | 14.9% | 16.2% | 9.2% | 10.3% | 11.0% | 12.2% | 10.9% | 12.3% | 9.7% | 10.0% | 15.1% | |
| 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.4% | 0.5% | 0.5% | 0.5% | 0.6% | 0.7% | 0.6% | |
| 2.1% | 1.7% | 2.3% | 2.1% | 2.2% | 1.9% | 3.2% | 2.6% | 2.4% | 2.0% | 2.2% | 1.7% | |
| 41.3% | 39.0% | 37.7% | 39.3% | 38.6% | 38.1% | 37.1% | 37.6% | 36.5% | 37.4% | 37.0% | 35.0% | |
| 38.5% | 42.3% | 42.7% | 47.8% | 47.1% | 46.4% | 46.2% | 46.9% | 46.6% | 48.4% | 46.9% | 44.1% | |
| 24.2% | 27.1% | 28.7% | 32.9% | 34.4% | 36.1% | 36.5% | 38.7% | 38.6% | 40.9% | 40.9% | 40.4% | |
| 3.5% | 3.5% | 3.4% | 3.5% | 3.4% | 3.3% | 3.1% | 3.0% | 2.9% | 2.9% | 2.8% | 2.5% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.